Alimera Sciences, Inc., based in Alpharetta, Georgia, is a biopharmaceutical company that specializes in the research, development and commercialization of prescription ophthalmic pharmaceuticals, and is dedicated to developing innovative, vision-improving treatments for diseases of the retina. Our commitment to retina specialists and their patients is manifest in our product development portfolio being studied to treat early- and late-stage diseases such as diabetic macular edema (DME), wet and dry age-related macular degeneration (AMD) and retinal vein occlusion.
Alimera Sciences’ advanced product candidate, ILUVIEN® has received its marketing authorization approval in Austria, Denmark, France, Germany, Italy, Norway, Portugal, Spain and the United Kingdom.
Alimera has received a positive outcome of the Repeat-Use Procedure for ILUVIEN® for the treatment of chronic diabetic macular edema (DME) in an additional 8 European Union countries. The regulatory process for these additional countries, consisting of Ireland, the Netherlands, Belgium, Luxembourg, Sweden, Finland, Poland and the Czech Republic, will now enter the national phase in which each country grants marketing authorization. Alimera Sciences is still seeking approval in the United States.
The proposed treatment consists of a tiny, cylindrical polymide tube that contains 190 µg of fluocinolone acetonide (FAc), a corticosteroid. Corticosteroids have a history of treating ocular diseases.
Alimera is committed to developing proactive solutions while remaining attuned to market needs and opportunities. Learn more about Alimera with the shareholder tools below.